Document is current
Any future updates will be listed below
-
Authors
Tayama, Sayoko
Miyamoto, Hideaki
Waki, Kotaro
Honda, Munenori
Matsuno, Kenshi
Yamasaki, Akira
Gushima, Ryosuke
Nagaoka, Katsuya
Naoe, Hideaki
Imuta, Masanori
Kawakami, Fumi
Komohara, Yoshihiro
Miyamaru, Satoru
Murakami, Daizo
Orita, Yorihisa
Tanaka, Yasuhito https://orcid.org/0000-0002-2473-6966
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (23755474)
- License Information
-
More Information
Article History
Received: 21 October 2024
Accepted: 4 January 2025
First Online: 25 February 2025
Declarations
:
: Yasuhito Tanaka received honoraria from AbbVie GK, Gilead Sciences, Inc, Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings Co., Ltd., OTSUKA Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, AstraZeneca, Eisai and HU frontier. He received research funds from AbbVie GK, FUJIREBIO Inc, Sysmex Corp, GlaxoSmithKline PLC., Gilead Sciences, Inc., Janssen Pharmaceutical K.K. and OTSUKA Pharmaceutical Co., Ltd.
: Due to the retrospective nature of the study, the institutional review board of Kumamoto University Hospital waived the need of obtaining informed consent.
